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1012-123 Safety and Tolerability of Fast Up-Titration of Carvedilol 
in Patients With Heart Failure
Mucio T. Oliveira, Jr., Juliano N. Cardoso, Lina M. Gonzales, Irineu B. Moreno, Airton R. 
Scipioni, Antonio C. Barretto, Jose A. Ramires, Heart Institute (InCor), University of Sao 
Paulo Medical School, Sao Paulo, Brazil, Brazil
Background: Although beta-blockers (BB) are now the cornerstone in the treatment of
congestive heart failure (CHF), many patients are still receiving inadequate doses, prob-
ably due to cautious prescription. We designed this study to evaluated the safety and tol-
erability of a fast up-titration of carvedilol soon after compensation.
Methods: After compensation, 31 consecutive hospitalized patients (pts) with left ventric-
ular ejection fraction (LVEF) <= 0.45 who had never used BB to treat CHF and with no
contraindication to BB were selected. Mean age was 55.5 years; 21 were men, and in
54.8% (n=17) inotropic support was needed for compensation. Mean LVEF was
0.29±0.07; mean left ventricular diastolic diameter was 7.0±0.7 cm. The initial dose of
3.125 mg bid was doubled each 2 days until day 8 (target dose of 25 mg bid). Criteria for
increment were HR >= 55 bpm, systolic blood pressure (SBP) >= 90 mmHg and no wors-
ening of CHF. A 6-minute walk test was performed on day zero, day 5, day 8 and day 30;
24 hours blood pressure continuous monitoring was performed on day zero and day 8.
Results: It was possible to reach the daily dose of 25 mg in 23/31 (74.2%) and 50 mg in
19/31 (61,2%) pts. The dose reached on day 8 was not different between pts who did or
did not required inotropic support for compensation. In the patients who reached the
dose of 25 mg/day the distance walked did not differ between days zero, 5, 8 and 30
(373.6±86.5 vs. 408.7±108.8 vs. 396.3±145.5 vs. 420.0±153.8 meters – p=0.18, 0.48
and 0.22). Mean weight gain was 2.1 kg (p=0.52), and SBP tended to be lower on day 8
(98.5±15.2 vs. 93.2±17.4 mmHg – p=0.06). The same tolerability was observed on day
30. The dose could not be increased in 9 patients, had to be reduced in 1, and had to be
withdrawn in 2.
Conclusion: Introduction and the fast up-titration of carvedilol can be done even after
inotropic support. Rapid up-titration was safe and can be done on lower intervals than
currently recommended.
1012-124 Carvedilol Improves Myocardial Perfusion in Conscious 
Dogs With Pacing Induced Dilated Cardiomyopathy
Lazaros A. Nikolaidis, Teresa Hentosz, Aaron Doverspike, Rhonda Huerbin, Lee 
Zourelias, Richard P. Shannon, Allegheny General Hospital, Pittsburgh, PA
Background: Both combined (β1, β2, α1, Carvedilol) and selective (β1, Metoprolol succi-
nate) adrenergic blockade have been associated with improved survival and clinical out-
comes in DCM. Whether there are important differences between the subclasses
remains controversial. Little is known with respect to differences in regional myocardial
perfusion between agents, especially in non-ischemic DCM. We have shown previously
that DCM in conscious dogs is associated with reduced subendocardial perfusion in the
absence of CAD.
Methods: We studied 15 conscious, chronically instrumented dogs with severe DCM
induced by 29 days of rapid pacing (240 min-1). We measured regional (subendocar-
dium: ENDO, subepicardium: EPI) myocardial perfusion in the LV and RV using neutron
activated microspheres before and after treatment with carvedilol (CARV: 25 mg po BID)
or metoprolol (MET: 100 mg po QD) for 3 days. Measurements of coronary perfusion
pressure (CPP=MAP-LVEDP-RA) and heart rate (HR) were recorded simultaneously to
insure comparable flow determinants.
Results: Both treatments were associated with significant (p< 0.01) decreases in HR
(CARV: - 49±6 from 126±26 min-1; MET: -42±3 from 124±6 min-1) and LVEDP (CARD: -
17±4 from 35±2 mmHg; MET: -14±3 from 36±2 mmHg) and significant increases in CPP
(CARV: +12±3 from 44±4 mmHg; MET: +14±3 from 41±3 mmHg).
CARV treatment increased LV ENDO (1.26±0.15 to 1.49±0.22 ml/min/g) but not LV EPI
flow (1.06±0.15 to 1.05±0.11 ml/min/g). In contrast, MET decreased LV ENDO
(1.17±0.12 to 1.05±0.13 ml/min/g, p<0.05 compared to CARV) but did not change LV EPI
(0.96±0.18 to 0.95±0.11 ml/min/g). CARV also increased RV ENDO (0.98±0.15 to
1.56±0.14 ml/min/g) while MET had no effect (1.18±0.19 to 1.12±0.25 ml/min/g, p< 0.05
compared to CARV).
Conclusion: Despite comparable effects on HR and CPP, CARV improves LV and RV
ENDO perfusion compared to MET. These differences are likely explained by α1 adrener-
gic blocking effects and may help to explain differences in clinical outcomes between
CARV and MET.
1012-125 Monotherapy With Extended Release Metoprolol 
Succinate Normalizes Exppression of Type-1 Protein 
Phosphatase in Left Ventricular Myocardium of Dogs 
With Chronic Heart Failure
Ramesh C. Gupta, Sudhish Mishra, Hideaki Morita, Sidney Goldstein, Hani N. Sabbah, 
Henry Ford Health System, Detroit, MI
Background: We previously showed that in dogs with chronic heart failure (HF) type-1
protein phosphatase (PP1) activity is increased and that this increase is due, in part, to
increased protein level of the alpha catalytic subunit of PP1 (PP1Calpha), an enzyme
considered to be a negative regulator of cardiac function. Increased PP1 activity in HF
can lead to dephosphorylation of phospholamban and consequently to abnormalities of
calcium cycling within the sarcoplasmic reticulum (SR) ultimately leading to LV systolic
and diastolic dysfucnction. In the same canine model of coronary microembolization-
induced HF, we showed that chronic monotherapy with extended release metoprolol suc-
cinate (ER-MET), a selective beta-1 adrenoceptor blocker, improves left ventricular (LV)
ejection fraction, reduces end-diastolic wall stress and improves myocardial relaxation. In
this study, we examined whether the improvement in LV systolic and diastolic function fol-
lowing chronic ER-MET therapy is associated with reduced PP1Calpha protein expres-
sion. Methods: Protein expression of PP1Calpha and calsequestrin (CSQ), an SR
protein not altered in HF, were measured in LV tissue of 6 dogs with HF treated long-term
(3 months) with ER-MET (100 mg once daily), 6 dogs with HF that were untreated and 6
normal dogs. In all instances, protein expression was measured in LV homogenate using
Western blots. Bands were quantified in densitometric units. Results: Protein expression
of PP1Calpha normalized to total tissue levels of CSQ increased significantly in
untreated HF dogs compared to normal dogs (0.99 + 0.05 vs. 0.47 + 0.02, P<0.05). In
dogs with HF treated with ER-MET, PP1Calpha protein expression decreased signifi-
cantly compared to untreated HF dogs (0.63 + 0.05 vs. 0.99 + 0.05, P<0.05), but
remained higher than that measured in normal dogs (0.63 + 0.05 vs. 0.47 + 0.02, P <
0.05). Conclusions: In dogs with chronic HF, PP1Calpha protein expression is
increased. Long-term therapy with ER-MET partially restores protein expression of
PP1Calpha to near normal levels. Normalization of PP1Calpha expression in HF can
explain, in part, the improvement of LV systolic and diastolic function seen with long-term
ER MET therapy.
1012-126 Contemporary Dosing of Angiotensin Converting 
Enzyme Inhibitors and Beta Blockers in Chronic Heart 
Failure: Report From the STAMINA:HFP (Study of 
Anemia in a Heart Failure Population) Registry
Javed Butler, Alan Miller, Ron M. Oren, Jalal K. Ghali, Biljana Pavlovic-Surjancev, Carla 
A. Sueta, Christopher M. O'Connor, Kathy Hebert, Mihai Gheorghiade, Douglas 
Schocken, William Cotts, Todd A. Schwartz, Kirkwood F. Adams, Jr., The STAMINA-HFP 
Investigators, University of North Carolina - Chapel Hill, Chapel Hill, NC
Background. Optimal utilization of angiotensin converting enzyme inhibitors (ACEI) and
beta blockers (BB) in heart failure requires treatment of eligible patients and use of doses
proven effective in clinical trials. However, doses commonly given patients with heart fail-
ure are not well studied.
Methods. The STAMINA-HFP Registry enrolled randomly selected patients with heart
failure from 6/24/02 to 5/15/03 in 12 specialty clinics and 45 community cardiology clinics.
Data on 656 return patients with EF < 40 who were taking either ACEI or BB and had
information available on doses of these drugs and use of angiotensin receptor blockers
(ARB) were analyzed. Doses were converted to milligram equivalents of enalapril or
metoprolol CR/XL. Extent of titration in each patient was evaluated as 1) % of the clinical
trial target dose in ACEI and BB mortality trials (%CTTD), (20 mg/d for enalapril and 200
mg/d of metoprolol CR/XL) and 2) % of the mean doses actually achieved in these trials
(%MDA) (16.6 mg/d for enalapril and 159 mg/d for metoprolol CR/XL).
Results. No patients were taking ACEI + ARB and no BB. Only 2.6% of patients were
taking BB + ACEI + ARB. The percentage of patients reaching at least CTTD or MDA and
the mean±SD dose equivalents achieved in the other patient groups are shown. 
Conclusions. Registry patients with documented systolic dysfunction were commonly 
treated with doses of ACEI and BB below MDA. Whether dose titration is limited by clini-
cal characteristics or other factors is under investigation.
1012-127 Neutral Endopeptidase Inhibition Augments the 
Vascular Actions of Bradykinin in Patients With Heart 
Failure on Chronic Angiotensin-Converting Enzyme 
Inhibitor Therapy
Nicholas L. Cruden, Keith A. A. Fox, David E. Newby, University of Edinburgh, Edinburgh, 
United Kingdom
Background Angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP)
degrade kinins. ACE inhibition potentiates bradykinin mediated vasodilatation and endot-
helial release of the pro-lytic factor, tissue plasminogen activator (t-PA) in patients with
chronic heart failure (CHF). We investigated whether additional NEP inhibition with thior-
Table
LVol 
(ml)
LVMass 
(gm)
C.O.(L/
min)
FS (%) VCF 
(circ/sec)
LVESS(gm/
cm2)
VCF:LVESS 
ratio
LVEF (%)by 
MUGA
Baseline 221 + 
68
168 + 73 3.0 + 
0.9
17.1+ 
6.3
0.63 + 
0.24
234 + 87 0.0032 + 
0.0021
28.2 + 8.4
6 
Months
197 + 
70 *
163 + 63 2.9 + 
0.8
23.4 + 
8.0 *
0.78 
+0.22 *
191+ 67 0.0048 
+0.0017 *
35.8+ 12.9 *
Drug(s) 
(N)
ACEI
CTTD
>100%
ACEI 
MDA
>100%
Enalmg
(mg/d)
BB
CTTD
>100%
BB
MDA
>100%
Metocrmg
(mg/d)
ACEI + 
BB
CTTD
>100%
ACEI + 
BB MDA
>100%
ACEI
(43)
42 42 17±16 -- -- -- -- --
BB
(156)
-- -- -- 32 33 113±82 -- --
BB+ARB
(96)
-- -- -- 48 49 161±114¶ -- --
BB+ACEI
(344)
54 54 19±15† 39 42 136±116*,§ 25 27
*Enalmg=milligram equivalents of enalapril, Metocrmg=milligram equivalents of 
metoprolol CR/XL, -- = not applicable.
†p=0.408 BB + ACEI versus ACEI alone, *p=0.012 BB alone versus BB + ACEI, 
¶p=0.001 BB alone versus BB + ARB,
§p=0.080 BB + ACEI versus BB + ARB
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phan could further augment the vascular actions of bradykinin in patients with CHF on
chronic ACE inhibitor therapy.
Methods 10 patients with CHF on chronic ACE inhibitor therapy received an intrabrachial
infusion of thiorphan (30 nmol/min) or saline placebo for 3 hours in a randomised, double
blind, cross over trial. Thiorphan or placebo was coinfused with Lys-des-Arg9-bradykinin
(B1 kinin receptor agonist; 1 - 10 nmol/min), bradykinin (B2 kinin receptor agonist; 30 -
300 pmol/min), atrial natriuretic peptide (10 -100 pmol/min) and sodium nitroprusside (2 -
8 mcg/min) in random order. Bilateral forearm blood flow (FBF) was recorded using strain
gauge plethysmography and plasma t-PA antigen determined using ELISA.
Results There were no changes in heart rate, blood pressure or noninfused FBF or t-PA
release during thiorphan or placebo infusion. Bradykinin, atrial natriuretic peptide and
sodium nitroprusside caused dose-dependent increases in infused FBF in all studies
(p<0.001). There were no significant changes in FBF during Lys-des-Arg9-bradykinin
infusion. Bradykinin but not Lys-des-Arg9-bradykinin or atrial natriuretic peptide caused a
dose dependent increase in t-PA antigen and estimated t-PA antigen release in all stud-
ies (p<0.001). Compared to placebo, thiorphan augmented the increase in infused FBF,
t-PA antigen and estimated t-PA antigen release (p<0.001, p=0.076, p<0.005 respec-
tively) to bradykinin but not atrial natriuretic peptide or sodium nitroprusside.
Conclusion In the presence of chronic systemic ACE inhibition, local NEP inhibition
potentiates bradykinin mediated vasodilatation and endothelial t-PA release. Given these
potential anti-ischaemic benefits, our findings support the hypothesis that combined
ACE/NEP inhibition may afford greater cardiovascular protection than ACE inhibition
alone.
1012-128 The Long-Term Impact of Initiating Treatment With the 
Angiotensin-Converting Enzyme Inhibitor Trandolapril 
After a Myocardial Infarction in Patients With Left 
Ventricular Dysfunction: A 10- to 12-Year Follow-Up 
Study
Pernille Buch, Soren Rasmussen, Steen Zabell Abildstrom, Lars Kober, Jan Carlsen, 
Christian Torp-Pedersen, Bispebjerg University Hospital, Copenhagen, Denmark, 
National Institute of Public Health, Copenhagen, Denmark
Background: Following a myocardial infarction (MI), treatment with angiotensin convert-
ing enzyme inhibitors reduces mortality and morbidity in patients with left ventricular dys-
function (LVD). However, long-term benefits remain unknown. We conducted a follow-up
study on the long-term effects of trandolapril use post-MI in patients with LVD.
Methods: In the Trandolapril Cardiac Evaluation (TRACE) study, 1,749 patients with LVD
(ejection fraction <35%) were randomized to trandolapril (n = 876) or placebo (n = 873) 3-
7 days post-MI. The study began in 1990 and closed in 1994; on–treatment follow-up
ranged from 2-4 years. National registries were used to track all deaths and hospitaliza-
tions until the end of 2002. We analyzed mortality with Cox proportional hazard models
and hospitalization with Poisson regression models (models adjusted for observation
time).
Results: Over 10-12 years of follow-up, a total of 1,281 deaths and 9,192 hospitalizations
were registered. Compared with the placebo group, the trandolapril group had a signifi-
cantly reduced risk of all-cause mortality and significantly reduced rates of all–cause
hospitalizations and congestive heart failure (CHF) hospitalizations (table).
Conclusion: In patients with LVD, use of trandolapril shortly after an MI for 2-4 years has
long-term benefits. Trandolapril reduces mortality and hospitalization rates for at least 10-
12 years. Further follow-up is required to determine the limit of these beneficial effects.
1012-129 Dual Angiotensin-II Suppression With Angiotensin-
Converting Enzyme Inhibitor and Irbesartan Improves 
Submaximal Exercise Time Without Changes in 
Exercise-Induced Neurohumoral Response in Patients 
With Congestive Heart Failure
Martine Blanchet, Richard Sheppard, Daniel Curnier, Jacques de Champlain, Pierre 
Sirois, Hélène Créo, André Roof, Lucette Whittom, Jean-Claude Tardif, Anique 
Ducharme, Normand Racine, Michel White, Montreal Heart Institute, Montreal, PQ, 
Canada, University of Sherbrooke, Sherbrooke, Canada
Background: The combination of an angiotensin-II receptor blocker (ARB) with an ACE
inhibitor (ACEi) provides benefits on clinical events and LV remodelling in patients with
congestive heart failure (CHF). The primary objective of this study was to investigate the
effects of Irbesartan versus placebo on submaximal exercise duration in patients with
CHF. The secondary objective was to assess the impact of such treatment on catechola-
mines and angiotensin-II (A-II) levels at rest, at 6 minutes, and at peak exercise during a
submaximal exercise test. Methods: Thirty-three patients with NYHA II or III CHF aged
56±12 years (mean±SD), LVEF 25.5±7.2%, and with exercise limited by dyspnea were
prospectively studied. Patients were blindly randomized to receive either Irbesartan 150
mg o.d. (n=22) or a placebo (n=11) for 6 months (m) in addition to optimal dose of ACEi
and beta-blockers. Maximal exercise capacity was evaluated using a Ramp protocol.
Submaximal exercise duration was assessed using a constant load protocol prescribed
at the level of the anaerobic threshold. Gas exchange was measured continuously during
both protocols. Results: (See Table). Conclusions: Dual A-II suppression with Irbesartan
and ACEi therapy improves submaximal exercise time by 23% without significant
changes in neurohumoral response at rest or during stress.
1012-130 Long-Term Effect of Statin on Exercise Tolerance, 
Cardiac Function and Clinical Outcome in Patients With 
Ischemic Chronic Heart Failure
Takahisa Yamada, Tsuyoshi Shimonagata, Naoyuki Misaki, Mitsutoshi Asai, Nobuhiko 
Makino, Hidetaka Kioka, Shunsuke Tamaki, Masatake Fukunami, Osaka Prefectural 
General Hospital, Osaka, Japan
Background: Statins have pleiotropic effects such as anti-inflammatory and vascular
protective effects, which would be beneficial for patients with chronic heart failure (CHF).
We sought to investigate the long-term effect of statins on exercise tolerance, cardiac
function and prognosis in patients with ischemic CHF.
Methods: We prospectively followed-up 66 consecutive ischemic CHF outpatients with
radionuclide left ventricular ejection fraction (RI-LVEF) < 40% for three years. At the
entry, we measured six minute walk distance (6MWD), left ventricular end-diastolic
dimension (LVDd) in echocardiography, RI-LVEF and plasma concentration of atrial natri-
uretic peptide (ANP), and thereafter these measurements were repeated at least every
year.
Results: There were no significant differences in age, gender, NYHA class, 6MWD,
LVDd or RI-LVEF at the entry between patients with (n=27) and without statins (n=39).
After the follow-up period of 2.8±0.5 years, patients with statins had a significant increase
in 6MWD and RI-LVEF and a decrease in LVDd and plasma level of ANP, while there
were no significant changes in these parameters in patients without statins. Furthermore,
during the follow-up period, the cardiac events were significantly (p=0.004) infrequently
observed in patients with (0%) than without statins (26%).
Conclusion: Long-term statin treatment might improve exercise tolerance and cardiac
function, resulting in an improvement in clinical outcome in patients with ischemic CHF.
Event Number of 
Events
Risk/Rate 
Ratio*
95% CI p Value
All-cause death
Overall 1990-2002 1,281 0.89† 0.80-0.99 0.04
Trial period 1990-1994 675 0.78† 0.67-0.91 0.001
After trial 1994-2002 606 1.03† 0.88-1.21 0.68
All-cause hospitalization
Overall 1990-2002 9192 0.92‡ 0.88-0.96 <0.001
Trial period 1990-1994 4599 0.92‡ 0.87-0.98 <0.005
After trial 1994-2002 4593 0.92‡ 0.87-0.98 0.005
CHF hospitalization
Overall 1990-2002 1,628 0.85‡ 0.77-0.93 <0.001
Trial period 1990-1994 817 0.76‡ 0.67-0.88 <0.001
After trial 1994-2002 811 0.94‡ 0.82-1.08 0.82
*Risk/rate ratio <1.0 favors trandolapril over placebo
†Risk ratio; ‡Rate ratio; CI, conficence interval
VO2 Peak 
ml/kg/min
Duration 
Max 
(sec)
Duration 
Submax 
(sec)
A-II
(pg/ml)
(6 m)
Bsl 6 m Bsl 6 m Bsl 6 m Rest Peak Ex
Irbe 
(n=22)
19.1±4.9 19.6
±4.3
554±127 578±
123
1043±507 1360*
±725
286±211 262±180
Placebo 
(n=11)
21.3±6.4 20.5
±6.6
630±140 647±
15
1581±664 1697
±743
239±118 310±272
Mean±SD; Irbe=Irbesartan: Bsl=baseline; Ex=exercise; *p=0.018 vs Bsl by Wilcoxon.
With statins Without statins p Value
at entry follow-up at entry follow-up (ANOVA)
6MWD (m) 363±73 392±68 374±88 363±100 0.008
RI-LVEF (%) 28.9±6.6 35.5±10.9 30.3±7.6 31.4±11.5 0.012
LVDd (mm) 58.3±5.4 56.4±6.7 60.5±7.4 61.6±7.7 0.02
ANP (pg/ml) 55.9±51.3 33.3±24.7 62.8±53.2 80.3±100.5 0.04
